Programmed Cell Death Ligand 1-Transfected Mouse Bone Marrow Mesenchymal Stem Cells as Targeted Therapy for...

Area of Science:

• Immunology
• Regenerative Medicine
• Rheumatology

Background:

• Programmed cell death 1 ligand (PD-L1) and its receptor (PD-1) are critical for immune regulation and immunotherapy.
• PD-1/PD-L1 interactions modulate T and B cell immunity, showing therapeutic potential in autoimmune diseases like rheumatoid arthritis (RA).

Purpose of the Study:

• To investigate the therapeutic efficacy of overexpressing PD-L1 in mouse bone marrow mesenchymal stem cells (MBMMSCs) for treating collagen-induced arthritis (CIA).

Main Methods:

• Constructed a recombinant PD-L1-lentiviral vector to overexpress PD-L1.
• Transfected MBMMSCs with the PD-L1 vector (PD-L1-MBMMSCs).
• Administered PD-L1-MBMMSCs to DBA/1j mice with CIA and evaluated therapeutic effects.

Main Results:

• PD-L1-MBMMSCs significantly suppressed the development of CIA in mice.
• Treatment ameliorated joint damage, reduced pro-inflammatory cytokine levels, and inhibited T and B cell activation.
• PD-L1-MBMMSCs modulated immune cell populations in the joints, decreasing dendritic cells and increasing regulatory T and B cells.

Conclusions:

• Overexpression of PD-L1 in MBMMSCs presents a promising therapeutic strategy for rheumatoid arthritis.
• PD-L1-MBMMSC-targeted therapy effectively suppresses autoimmune arthritis by modulating immune responses and cell populations.